Capricor Therapeutics, Inc. (CAPR) Financial Statements
Capricor Therapeutics, Inc. (CAPR) reported trailing twelve-month revenue of $0 (up 1.5% year on year) and net income of -$129.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$129.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAPRCapricor Therapeutics, Inc.Follow CAPR — free
—
Price chart with a free account
- Market cap
- 344.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4 | 0.2 | 0.5 | 4.8 | 5.5 | 4.0 | 2.7 | 1.7 | 1.0 | 0.3 | 0.2 | 2.6 | 25.2 | 22.3 | 0.0 | — | |
| Research & development | 4.1 | 2.6 | 5.2 | 7.8 | 13.8 | 16.0 | 10.8 | 12.1 | 5.1 | 8.5 | 13.6 | 21.8 | 36.4 | 50.0 | 84.5 | 99.7 | |
| Operating income | -4.9 | -2.1 | -6.9 | -6.0 | -12.6 | -17.0 | -12.9 | -15.3 | -7.7 | -13.7 | -20.9 | -29.7 | -24.1 | -42.6 | -108.1 | -135.2 | |
| Pre-tax income | — | — | — | — | — | — | — | — | — | — | — | — | — | -40.5 | -105.0 | -129.4 | |
| Income tax | — | 0.0 | — | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | |
| Net income | -1.1 | -2.1 | -8.9 | -6.2 | -12.9 | -18.8 | 2.4 | -15.2 | -7.6 | -13.7 | -20.0 | -29.0 | -22.3 | -40.5 | -105.0 | -129.4 | |
| Diluted EPS ($) | -0.13 | -0.21 | -0.85 | -0.53 | -0.81 | -1.01 | 0.10 | -5.17 | -2.06 | -0.88 | -0.87 | -1.18 | -0.83 | -1.15 | -2.26 | -2.23 | |
| Diluted shares (mn) | — | — | — | — | — | — | 26.8 | 2.9 | 3.7 | 15.6 | 23.1 | 24.6 | 26.8 | 35.2 | 46.5 | — |
USD millions · SEC XBRL
Capricor Therapeutics, Inc. — questions
- What is Capricor Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 1.5% year on year, from its 10-Q and 10-K filings.
- What is Capricor Therapeutics, Inc.'s net income?
- -$129.4M over the twelve months to 2026-06-30.
- What is Capricor Therapeutics, Inc.'s free cash flow?
- -$129.8M over the twelve months to 2026-06-30.
- What are Capricor Therapeutics, Inc.'s diluted earnings per share?
- $-2.23 over the twelve months to 2026-06-30.
Every figure on this page comes from Capricor Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.